Aurora (TSX:ACB) CEO Foresees Major Marijuana Stock Carnage in 2020

With the company’s CEO predicting “carnage” for marijuana stocks in 2020, investors should avoid taking a position on Aurora Cannabis stock for now.

| More on:
Businessman looking at a red arrow crashing through the floor

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Cannabis stocks are the fallen stars in 2019. Investors are losing interest in cannabis companies because of their mounting losses, controversies, and scandals. Since April, the market values of big and small players are dropping significantly. The key to regaining the trust of investors is for the marijuana stocks to show profitability.

According to Terry Booth, CEO of Aurora Cannabis (TSX:ACB)(NYSE:ACB), the turbulence is not over, and carnage is looming over the next year. Booth is not worrying about the demand for cannabis. He sees the need for producers to reduce production costs in a market beset by oversupply.

Constant disappointment

Sadly, marijuana investments have been a continual disappointment for investors. It appears that marijuana companies, including Aurora, are presenting ambitious guidance. Instead of delivering, Aurora is burning cash and diluting equity. As a result, the stock is suffering.

As of this writing, Aurora’s market capitalization is down to $3.42 billion from $7.63 billion in late August. Similarly, the price has fallen to $3.26 per share. On a year-to-date basis, Aurora is down 52%.

Last month, the company was able to secure a US$400 million at-the-market equity financing program. Booth said the funding would allow this top cannabis producer to handle its operations during the current downtrend.

The high cost of production ($4-$5 per gram) is hurting other cannabis companies. In the coming months, the carnage in the production area will no longer be tolerable. Aurora can withstand the effect, as it is a low-cost player. It’s producing cannabis at less than $1. But Aurora will not get into a price war.

However, in case of a price war due to oversupply, the company is best prepared to deal with it. To show good faith and counter the negative impression, Booth bought 270,000 worth of Aurora shares (nearly $1 million) in late November.

Industry outlook

Aurora’s CEO summarized the industry situation today. Booth said, “Remember, they used to value our companies based on the size of our vault and then based it on the size of our licence, and then they based on the funding capacity and they’re finally moving towards can these guys make money.”

Aurora’s September quarterly report was horrendous. Likewise, with the sizeable convertible debt falling due on March 9, 2020, the company decided for all debtholders to convert into common shares. While the dilution was painful to shareholders, it was the only way Aurora can attract new investors.

The net effect of this convertible debt conversion is a reduction of the market cap to $2.6 billion, with the stock price settling at $2.50 per share. Fortunately, with $153 million in cash as of the quarter ended September 30, 2019, plus the US$400 million funding, Aurora can cover capital-spending plans in 2019.

Precarious state

The ongoing dilution at Aurora is a deal buster to would-be investors. However, the conversion of its debentures in 2020 as well the $190 million reductions in capital spending will improve the company’s liquidity position.

Aurora is making canny moves to ensure a bright long-term future and maintain its industry-leading position. For investors, fasten your seat belts and adopt a wait-and-see attitude. The ride is going to be turbulent in 2020.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »